drugset
drugset / Trial / NCT02656797

Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

NCT02656797 ↗

Phase 2 Completed 13 enrolled Soroka University Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.

Timeline

Start
2018-01-30
Primary completion
2021-06-01
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 0.4 % Topical

Indications

cutaneous leishmaniasis